I-Corps: Photobiomodulation device for the treatment of neurodegenerative diseases

I-Corps：用于治疗神经退行性疾病的光生物调节装置

• 批准号: 2037640
• 负责人: Anthony Costa
• 金额: $ 5万
• 依托单位: Icahn School of Medicine at Mount Sinai
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2021-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2037640&HistoricalAwards=false
• 关键词: Corps; Photobiomodulation; device; treatment; neurodegenerative; Corps; Photobiomodulation; device; treatment; neurodegenerative

The broader impact/commercial potential of this I-Corps project is the development of a novel technology to slow the progression of Alzheimer’s Disease (AD). AD is a common and devastating disease that currently affects 1 in 3 seniors within the United States and will cost the nation over $1 trillion per year by 2050. The pathology of the disease has remained elusive through decades of study, and the field is awash in failed drug and device trials. The proposed technology helps reduce the impact of the disease.This I-Corps project explores translation of an implantable technology that targets a AD pathway adjacent to the disease pathology. It focuses on treatment reduction rather than curative outcomes. Initial outcome metrics will focus on biomarkers specific to the mechanism of the device and the longevity of effect. Clinical outcomes will center on a battery of cognitive testing, including MOCA and MMSE scores.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力是开发一种新技术，以减缓阿尔茨海默氏病（AD）的发展。 AD是一种常见且毁灭性的疾病，目前会影响美国境内三分之一的老年人，到2050年，全国每年将使全美损失超过1万亿美元。在数十年的研究中，该疾病的病理仍然难以捉摸，并且该领域因药物和设备试验而失败。提出的技术有助于减少疾病的影响。该I-Corps项目探讨了针对疾病病理相邻的AD途径的可植入技术的翻译。它的重点是减少治疗而不是治愈结果。最初的结果指标将集中于针对设备机制和效果寿命的生物标志物。临床结果将集中在包括MOCA和MMSE分数在内的一系列认知测试中。该奖项反映了NSF的法定任务，并使用基金会的知识分子优点和更广泛的影响评估标准，被认为是通过评估来获得的支持。